Open Access Open Access  Restricted Access Subscription or Fee Access

Revolutionizing Cancer Treatment through Nanoparticle-Based Drug Delivery Systems

Kanika Maheshwari

Abstract


Cancer is a leading cause of death worldwide, and the treatment options available have significant limitations, including toxicity, low efficacy, and drug resistance. Nanotechnology has made significant progress in recent years, resulting in the emergence of drug delivery systems based on nanoparticles that are used for cancer treatment. These systems offer numerous benefits, including targeted drug delivery, increased drug stability, and reduced toxicity. Nanoparticle-based drug delivery systems are a promising innovation that has the potential to revolutionize cancer treatment. These systems can be designed to selectively target cancer cells, while sparing healthy cells, leading to increased efficacy and reduced toxicity. In addition, nanoparticles can be designed to release drugs selectively in response to specific triggers, such as changes in pH or temperature, which can improve drug delivery to the tumor site while minimizing side effects.

This article provides an overview of the different types of nanoparticle-based drug delivery systems currently in development for cancer treatment, including liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles. The article also addresses the challenges related to the development and clinical application of these systems, which include regulatory obstacles and manufacturing complexities.  Overall, the use of nanoparticle-based drug delivery systems holds great promise for revolutionizing cancer treatment. While there are still significant challenges to overcome, continued research and development in this field have the potential to significantly improve patient outcomes and quality of life.


Full Text:

PDF

References


Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical pharmacology and therapeutics, 83(5), 761-769.

Torchilin, V. P. (2006). Multifunctional nanocarriers. Advanced drug delivery reviews, 58(14), 1532-1555.

Peer, D., Karp, J. M., Hong, S., & Farokhzad, O. C. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology, 2(12), 751-760.

Davis, M. E., Chen, Z. G., & Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery, 7(9), 771-782.

Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65(1), 36-48.

Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS nano, 3(1), 16-20.

Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews, 41(7), 2971-3010.

Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine, 6(4), 715-728.

Cho, K., Wang, X., Nie, S., Chen, Z. G., & Shin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research, 14(5), 1310-1316.

Jain, R. K., Stylianopoulos, T., & Munn, L. L. (2014). Delivery of nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 12(6), 1-17.

Barenholz, Y. C. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of controlled release, 160(2), 117-134.

Guo, P., Huang, J., Moses, M. A., & Wang, C. (2015). Nucleic acid aptamers and cancer therapy. In Seminars in radiation oncology (Vol. 25, No. 1, pp. 20-29). WB Saunders.

Hu, Q., Sun, W., Wang, C., & Gu, Z. (2018). Recent advances of cocktail chemotherapy by combination drug delivery systems. Advanced drug delivery reviews, 132, 96-107.

Fan, Y., & Moon, J. J. (2015). Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines, 3(3), 662-685.

Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. Journal of controlled release, 161(2), 175-187.

Danhier, F. (2016). To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?. Journal of controlled release, 244, 108-121.

Wu, Y., Wu, T., Wu, J., & Zhao, L. (2019). Strategies for enhancing the tumor accumulation and penetration of nanoparticles. Journal of controlled release, 296, 42-62.

Li, Y., Liu, R., Shi, Y., Zhang, Z., & Zhang, X. (2020). Emerging nanotechnologies for liquid biopsy: the detection and analysis of circulating tumor cells and extracellular vesicles. Advanced materials, 32(25), 1901697.

Kuai, R., Yuan, W., Son, S., Nam, J., Xu, Y., Fan, Y., ... & Moon, J. J. (2020). Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Science Advances, 6(24), eaaz9249.




DOI: https://doi.org/10.37628/ijn.v8i2.946

Refbacks

  • There are currently no refbacks.